Dynavax Technologies Corp financial data

Symbol
DVAX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2100 Powell Street, Suite 720, Emeryville, CA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.31K % +0.05%
Quick Ratio 96.2 % +13.9%
Debt-to-equity 59.5 % -6.56%
Return On Equity 4.3 %
Return On Assets 2.7 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 124M shares -5.21%
Common Stock, Shares, Outstanding 125M shares -3.15%
Entity Public Float 800M USD -11.1%
Common Stock, Value, Issued 125K USD -3.85%
Weighted Average Number of Shares Outstanding, Basic 130M shares +1.02%
Weighted Average Number of Shares Outstanding, Diluted 133M shares +3.58%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 277M USD +19.4%
Research and Development Expense 61.6M USD +12.1%
Costs and Expenses 281M USD +4.48%
Operating Income (Loss) -4.12M USD +88.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 30.9M USD +666%
Income Tax Expense (Benefit) 3.55M USD +75.4%
Net Income (Loss) Attributable to Parent 27.3M USD +3119%
Earnings Per Share, Basic 0.21 USD/shares
Earnings Per Share, Diluted 0.2 USD/shares +600%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 95.9M USD -36.2%
Inventory, Net 70.1M USD +31.5%
Assets, Current 849M USD -1.19%
Property, Plant and Equipment, Net 39M USD +4.57%
Operating Lease, Right-of-Use Asset 21.6M USD -11%
Goodwill 1.95M USD -5.85%
Other Assets, Noncurrent 74.8M USD +0.59%
Assets 986M USD -1.09%
Accounts Payable, Current 9.06M USD +72.8%
Accrued Liabilities, Current 61.1M USD +23.5%
Liabilities, Current 78.6M USD +26.4%
Operating Lease, Liability, Noncurrent 26.4M USD -11.2%
Other Liabilities, Noncurrent 244K USD +230%
Liabilities 389M USD +3.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.72M USD -124%
Retained Earnings (Accumulated Deficit) -903M USD +2.94%
Stockholders' Equity Attributable to Parent 597M USD -4.06%
Liabilities and Equity 986M USD -1.09%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.7M USD -160%
Net Cash Provided by (Used in) Financing Activities -4.2M USD -36%
Net Cash Provided by (Used in) Investing Activities 2.83M USD
Common Stock, Shares Authorized 278M shares 0%
Common Stock, Shares, Issued 125M shares -3.15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.3M USD +34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 96.2M USD -36.1%
Deferred Tax Assets, Valuation Allowance 173M USD -4.36%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.24 pure +677%
Deferred Tax Assets, Gross 179M USD -5.33%
Operating Lease, Liability 30.6M USD -10.7%
Payments to Acquire Property, Plant, and Equipment 749K USD -41.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 24.7M USD -55.4%
Lessee, Operating Lease, Liability, to be Paid 41.3M USD -14%
Property, Plant and Equipment, Gross 73.2M USD +5.84%
Operating Lease, Liability, Current 4.18M USD -7.14%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.51M USD -6.68%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.94M USD -8.73%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.7M USD -22.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.46M USD +5.49%
Deferred Tax Assets, Operating Loss Carryforwards 77.8M USD -19.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 12.4M USD +2.47%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.44M USD +6.46%
Operating Lease, Payments 1.9M USD +11.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 6.82M USD -24.6%
Share-based Payment Arrangement, Expense 0 USD -100%
Interest Expense 6.78M USD +0.49%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%